Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt Nephropathy

NCT00464776 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Aliskiren
DRUG: Aliskiren
DRUG: Aliskiren
DRUG: Aliskiren

Sponsor

Novartis